The content of ecstasy tablets: Implications for the study of their long-term effects

Addiction

Volumn 97, Issue 12, 2002, Pages 1531-1536

  Cole, Jon C ^a   Bailey, Mike ^b   Sumnall, Harry R ^a   Wagstaff, Graham F ^a   King, Les A ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b FORENSIC SCIENCE SERVICE   (United Kingdom)

Author keywords

Dose; Drug purity; Ecstasy; MDMA; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ANALYTIC METHOD; ARTICLE; COMORBIDITY; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG PURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG TERM EXPOSURE; NEUROTOXICITY; NUTRITIONAL STATUS; TABLET MANUFACTURE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SEROTONIN AGENTS; TABLETS;

EID: 0036913518     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1360-0443.2002.00222.x     Document Type: Article

References (53)

1. Aghajanian, G. K. & Lieberman, J. A. (2001) Response. Neuropsychopharmacology, 24, 335-336.
2. Arimany, J., Medallo, J., Pujol, A., Vingut, A., Borondo, J. C., Valverde, J. L. (1998) Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; 'eve'): Case report. American Journal of Forensic Medicine and Pathology, 19, 148-151.
3. Axt, K. J., Mamounas, L. A., Molliver, M. E. (1994) Structural features of amphetamine neurotoxicity in the brain. Amphetamine and its analogs: Psychopharmacology, toxicology and abuse. In: Mamounas, L. A. ed., pp. 315-367. Neurotoxicity. San Diego, CA: Academic Press.
4. Baggott, M., Heifets, B., Jones, R. T., Mendelson, J., Sferios, E., Zehnder, J. (2000) Chemical analysis of Ecstasy pills. Journal of the American Medical Association, 284, 2190-2191.
5. Battaglia, G., Sharkey, J., Kuhar, M. J., De Souza, E. B. (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): Assessment using quantitative autoradiography. Synapse, 8, 249-260.
6. Battaglia, G., Zaczek, R., De Souza, E. B. (1990) MDMA effects in brain: pharmacologic profile and evidence of neurotoxicity from neurochemical and autoradiographic studies. In: Peroutka, S. J., ed. Ecstasy: the Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA, pp. 171-199. Boston: Kluwer Academic Publishers.
7. Bolla, K. I., McCann, U. D., Ricaurte, G. A. (1998) Memory impairment in abstinent MDMA ('Ecstasy') users. Neurology, 51, 1532-1537.
8. Briley, M., Chopin, P., Moret, C. (1990) Effect of serotonergic lesion on 'anxious' behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology, 101, 187-189.
9. Briley, M., Chopin, P., Moret, C. (1991) The role of serotonin in anxiety: Behavioural approaches. In: Briley, M. & File, S. E., eds. pp. 56-73. New Concepts in Anxiety Basingstoke: Macmillan Press.
10. Cole, J. C. & Sumnall, H. R. (2002) Altered states: the clinical effects of ecstasy. Pharmacology and Therapeutics, in press.
11. Croft, R. J., Klugman, A., Baldeweg, T., Gruzelier, J. H. (2001) Electrophysiological evidence of serotonergic impairment in long-term MDMA ('ecstasy') users. American Journal of Psychiatry, 158, 1687-1692.
12. Fox, H. C., Parrott, A. C., Turner, J. J. D. (2001) Ecstasy use: Cognitive deficits related to dosage rather than self-reported problematic use of the drug. Journal of Psychopharmacology, 15, 273-282.
13. Frederick, D. L. & Paule, M. G. (1997) Effects of MDMA on complex brain function in laboratory animals. Neuroscience and Biobehavioral Reviews, 21, 67-78.
14. Gijsman, H. J., Verkes, R. J., van Gerven, J. M. A., Cohen, A. F. (1999) MDMA study. Neuropsychopharmacology, 21, 597.
15. Green, A. R., Cross, A. J., Goodwin, G. M. (1995) Review of the pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA or 'ecstasy'). Psychopharmacology, 119, 247-260.
16. Hatzidimitriou, G., McCann, U. D., Ricaurte, G. A. (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±) 3,4-methylenedioxymethamphetamine seven years previously: Factors influencing abnormal recovery. Journal of Neuroscience, 19, 5096-5107.
17. Hegadoren, K. M., Baker, G. B., Bourin, M. (1999) 3,4-Methylenedioxymethamphetamine analogues of amphetamine: Defining the risks to humans. Neuroscience and Biobehavioral Reviews, 23, 539-553.
18. Kahn, R. S., Asnis, G. M., Wetzler, S., van Praag, H. M. (1988) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology, 96, 360-364.
19. Kalia, M., O'Callaghan, J. P., Miller, D. B., Kramer, M. (2000) Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. Brain Research, 858, 92-105.
20. Kish, S. J. (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacology, Biochemistry and Behavior, 71, 845-855.
21. Lehmann, J., De Souza, E. B., Culp, S., Zaczek, R. (1992) Regional distribution to recovery of 5-HT levels after administration of 'atrophins' MDMA and D,L-fenfluramine: Stereospecificity and comparison with 5,7-dihydroxytryptamine. Annals of the New York Academy of Sciences, 648, 291-295.
22. Lenton, S., Boys, A., Norcross, K. (1997) Raves, drugs and experience: Drug use by a sample of people who attend raves in Western Australia. Addiction, 92, 1327-1337.
23. Lew, R., Sabol, K. E., Chou, C., Vosmer, G. L., Richards, J., Seiden, L. S. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. Journal of Pharmacology and Experimental Therapeutics, 276, 855-865.
24. Lieberman, J. A. & Aghajanian, G. K. (1999) Caveat emptor: Researcher beware. Neuropsychopharmacology, 21, 471-473.
25. Marston, H. M., Reid, M. E., Lawrence, J. A., Olverman, H. J., Butcher, S. P. (1999) Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology, 144, 67-76.
26. McCann, U. D. & Ricaurte, G. A. (2001) Caveat emptor, editors beware. Neuropsychopharmacology, 24, 333-334.
27. McCann, U. D., Selden, L. S., Rubin, L. J., Ricaurte, G. A. (1997) Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence. Journal of the American Medical Association, 278, 666-672.
28. McKenna, D. J. & Peroutka, S. J. (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Journal of Neurochemistry, 54, 14-22.
29. Milroy, C. M., Clark, J. C., Forrest, A. R. W. (1996) Pathology of deaths associated with 'ecstasy' and 'eve' misuse. Journal of Clinical Pathology, 49, 149-153.
30. Morgan, M. J. (2000) Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology, 152, 230-248.
31. Murphy, D. L., Mueller, E. A., Hill, J. L., Tolliver, T. J., Jacobsen, F. M. (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology, 98, 275-282.
32. O'Shea, E., Granados, R., Esteban, B., Colado, M. I., Green, A. R. (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology, 37, 919-926.
33. Parrott, A. C. (2000) Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change. Neuropsychobiology, 42, 17-24.
34. Parrott, A. C., Milani, R., Parmar, R., Turner, J. J. D. (2001) Recreational ecstasy/MDMA and other drug users from Britain and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology, 159, 77-82.
35. Parrott, A. C., Sisk, E., Turner, J. J. D. (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug and Alcohol Dependence, 60, 105-110.
36. Ramsey, J. D. (1999) TICTAC, Version 4.4. Norwich: Stationery Office.
37. Ramsey, J. D., Butcher, M. A., Murphy, M. F., Lee, T., Johnston, A., Holt, D. W. (2001) A new method to monitor drugs at dance venues. British Medical Journal, 323, 603.
38. Ricaurte, G. A., Markowska, A. L., Wenk, G. L., Hatzidimitriou, G., Wlos, J., Olton, D. S. (1993) 3,4-Methylenedioxymethamphetamine, serotonin and memory. Journal of Pharmacology and Experimental Therapeutics, 266, 1097-1105.
39. Ricaurte, G. A., Yuan, J., McCann, U. D. (2000) (±) 3,4-methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: Studies in animals. Neuropsychobiology, 42, 5-10.
40. Rothe, M., Pragst, F., Spiegel, K., Harrach, T., Fischer, K., Kunkel, J. (1997) Hair concentration and self-reported abuse history of 20 amphetamine and ecstasy users. Forensic Science International, 89, 111-128.
41. Sabol, K. E., Lew, R., Richards, J. B., Vosmer, G. L., Selden, L. S. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. Journal of Pharmacology and Experimental Therapeutics. 276, 846-854.
42. Saunders, N. (1997) Ecstasy Reconsidered. London: Nicholas Saunders.
43. Schifano, F., Di Furia, L., Forza, G., Minicuci, N., Bricolo, R. (1998) MDMA ('ecstasy') consumption in the context of polydrug abuse: A report on 150 patients. Drug and Alcohol Dependence, 52, 85-90.
44. Selden, L. S., Woolverton, W. L., Lorens, S. A., Williams, J. E. G., Corwin, R. L., Hata, N., Olimski, M. (1993) Behavioral consequences of partial monoamine depletion in the CNS after methamphetamine-like drugs: The conflict between pharmacology and toxicology. NIDA Research Monograph, 136, 34-52.
45. Sherlock, K., Wolff, K., Hay, A. W. M., Conner, M. (1999) Analysis of illicit ecstasy tablets: Implications for clinical management in the accident and emergency department. Journal of Accident and Emergency Medicine, 16, 194-197.
46. Sprague, J. E., Everman, S. L., Nichols, D. E. (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology, 19, 427-442.
47. Spruit, I. P. (1999) Ecstasy use and policy responses in the Netherlands. Journal of Drug Issues, 29, 653-678.
48. Steele, T. D., McCann, U. D., Ricaurte, G. A. (1994) 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy'): Pharmacology and toxicology in animals and humans. Addiction, 89, 539-551.
49. Verkes, R. J., Gijsman, H. J., Pieters, M. S. M., Schoemaker, R. C., de Visser, S., Kuijpers, M., Pennings, E. J. M., de Bruin, D., van de Wijngaart, G., van Gerven, J. M. A., Cohen, A. F. (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology, 153, 196-202.
50. Vollenweider, F. X., Gamma, A., Liechti, M., Huber, T. (1999) Is a single dose of MDMA harmless? Neuropsychopharmacology, 21, 598-600.
51. Vollenweider, F. X., Jones, R. T., Baggott, M. J. (2001) Caveat emptor, editors beware. Neuropsychopharmacology, 24, 461-463.
52. White, S. R., Obradovic, T., Imel, K. M., Wheaton, M. J. (1996) The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system. Progress in Neurobiology, 49, 455-479.
53. World Health Organization (1997) Amphetamine-Type Stimulants. A report from the WHO meeting on amphetamines, MDMA and other psychostimulants. Geneva, 12-16 November 1996. Geneva: WHO.